NLS Pharmaceutics Ltd. Announces Expected Implementation Of 1-For-40 Reverse Share Split
NLS Pharmaceutics Ltd. Announces Expected Implementation Of 1-For-40 Reverse Share Split
No fractional shares will be issued as a result of the Reverse Split and cash in lieu will be provided for any fractional shares resulting from the Reverse Split on a per shareholder basis. The Reverse Split will not impact any shareholder's percentage ownership of NLS or voting power, except for minimal effects resulting from the treatment of fractional shares. All options and warrants of the Company outstanding prior to the split will be appropriately adjusted.NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that a reverse share split of the Company's issued and outstanding common shares, par value CHF 0.02 per share (the "Common Shares"), at a ratio of 1-for-40 is expected to be implemented at market open on September 27, 2024 (the "Reverse Split"). The Company's Common Shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on September 27, 2024, under the Company's existing trading symbol "NLSP", but will trade under a new CUSIP Number, H57830137. A notice of the reverse split will be filed with the commercial registry of the Canton of Zurich, Switzerland, on September 27, 2024. As a result, the reverse split will become effective in Switzerland on September 27, 2024, before Nasdaq market opening at 9:30 am (EST). Following its effectiveness in Switzerland, the reverse split will be published in the Swiss Official Gazette of Commerce (SOGC) on October 1, 2024, at 00:01am (Swiss time).
NLS製藥有限公司（納斯達克：NLSP）（納斯達克：NLSPW）（"NLS"或"公司"）是一家瑞士臨床階段的生物製藥公司，致力於發現和開發創新療法，用於治療罕見和複雜的中樞神經系統疾病的患者。今天宣佈，公司預計將對已發行和流通的每股面值爲0.02瑞士法郎的普通股（"普通股"）進行1比40的轉股，此反向拆分將於2024年9月27日開市時實施（"反向拆分"）。預計公司的普通股將於2024年9月27日開市時在納斯達克資本市場上以分拆後的基礎進行交易，交易代碼爲"NLSP"，但將以新的CUSIP編號H57830137交易。反向拆分通知將於2024年9月27日在瑞士蘇黎世州的商業註冊處進行備案。因此，反向拆分將於2024年9月27日在瑞士生效，在納斯達克市場開盤時間上午9:30（東部標準時間）前。在瑞士生效後，反向拆分將於2024年10月1日瑞士時間凌晨00:01被刊登在瑞士《官方商報》上。
The reverse share split was approved by the Company's shareholders at the Company's extraordinary shareholders' meeting held on September 18, 2024 (the "Meeting").
逆向拆股已獲公司股東於2024年9月18日舉行的公司股東特別大會（"大會"）批准。
After giving effect to the Reverse Split of the Company's Common Shares, each 40 Common Shares will be combined into one Common Share, such that the Company's 46,880,000 Common Shares outstanding will be reduced to approximately 1,172,000 Common Shares outstanding.
在公司普通股逆向拆股生效後，每40股普通股將合併爲一股普通股，公司現有的46,880,000股普通股將減少至大約1,172,000股普通股。
No fractional shares will be issued as a result of the Reverse Split and cash in lieu will be provided for any fractional shares resulting from the Reverse Split on a per shareholder basis. The Reverse Split will not impact any shareholder's percentage ownership of NLS or voting power, except for minimal effects resulting from the treatment of fractional shares. All options and warrants of the Company outstanding prior to the split will be appropriately adjusted.
逆向拆股不會發行碎股，對於由於逆向拆股而產生的碎股，將按股東比例提供現金替代。逆向拆股不會影響任何股東對NLS的持股比例或投票權，除了由於碎股處理而產生的微小影響。在拆分前未行使的所有期權和權證將得到適當調整。
譯文內容由第三人軟體翻譯。